Streetbeat News

Products Services

AAPL

The iPhone 15 is experiencing lower than expected sales in China, leading resellers to offer significant discounts in an effort to boost sales. This situation indicates a potential challenge for Apple in one of its key markets.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 4:01 pm

IMCR

Immunocore Holdings (NASDAQ:IMCR) has received mixed analyst ratings over the last three months, with a recent shift towards more bullish perspectives. Analysts from firms including Oppenheimer, Canaccord Genuity, Needham, and Mizuho have updated their ratings and price targets, reflecting an optimistic outlook with an average 12-month price target of $79.25, up from $72.33. The company, a late-stage biotech focusing on TCR bispecific immunotherapies, has shown strong financial performance with significant revenue growth, high net margin, and effective debt management.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 4:00 pm

DOGEUSD

FLOKIUSD

SHIBUSD

Floki Inu (FLOKI) developers propose to burn 190 billion tokens, accounting for 2% of its circulating supply, amid a 67.5% weekly rally. The community will vote on this proposal. Web3 investment firm DWF Labs plans to purchase $10 million in FLOKI tokens. A request has been made to list Floki on Binance due to its potential as a top memecoin. Floki Inu, inspired by Elon Musk's pet, is seen as a potential rival to Dogecoin (DOGE) and Shiba Inu (SHIB).

Portfolio Pulse from Khyathi Dalal

February 29, 2024 | 4:00 pm

QCOM

Recent analysis of options trading activity for Qualcomm (NASDAQ:QCOM) shows a bullish sentiment among investors, with 56% of trades being bullish and 43% bearish. Notable trades include both puts and calls, targeting a price range of $105.0 to $175.0 for Qualcomm over the last 3 months. The company, a major player in wireless technology and chip design, is currently trading at $156.94, up 0.7%, but may be overbought according to RSI readings. Analysts have issued varied ratings, with a consensus target price of $163.0.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 3:47 pm

IRWD

Ironwood Pharmaceuticals' shares dropped following the announcement that its Phase 3 trial of apraglutide failed to meet two key secondary endpoints. The trial was evaluating the efficacy of a once-weekly subcutaneous administration of apraglutide.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 3:45 pm

TSLA

Ford Motor Company (NYSE:F) has announced that its electric vehicle (EV) customers, specifically those owning Ford F-150 Lightning and Mustang Mach-E, now have access to Tesla Inc's (NASDAQ:TSLA) Supercharger network. This access includes over 15,000 Tesla Superchargers, effectively doubling the charging options for Ford's EV customers. The partnership, which was first announced in May 2023, allows Ford EV owners to use a fast-charging adapter for free until June 30, 2024, after which it will cost $230. This collaboration is seen as a significant step towards improving EV infrastructure and reducing barriers to EV adoption.

Portfolio Pulse from Chris Katje

February 29, 2024 | 3:43 pm

CPRX

RNA

SILK

As of Feb. 29, 2024, Avidity Biosciences (RNA), Catalyst Pharmaceuticals (CPRX), and Silk Road Medical (SILK) are considered overbought in the health care sector, with RSI values above 70, indicating potential short-term performance concerns. Avidity Biosciences reported a wider-than-expected quarterly loss but expects a transformative year with its Phase 3 HARBOR trial. Catalyst Pharmaceuticals exceeded quarterly expectations with robust revenue growth. Silk Road Medical posted a narrower-than-expected loss, focusing on deepening TCAR adoption.

Portfolio Pulse from Avi Kapoor

February 29, 2024 | 3:40 pm

ENVB

IRWD

LPSN

SCTL

VLCN

U.S. stocks showed mixed performance with the Nasdaq gaining 100 points following the release of PCE data indicating a slight ease in inflation from 2.6% to 2.4%. Societal CDMO, Enveric Biosciences, and Volcon saw significant stock increases due to acquisition and licensing news, while LivePerson, The Chemours Company, and Ironwood Pharmaceuticals experienced sharp declines due to disappointing financial results and trial outcomes.

Portfolio Pulse from Avi Kapoor

February 29, 2024 | 3:40 pm

RNLX

Renalytix Plc shares are trading higher following the announcement that the US has approved adding the company's kidneyintelX.dkd to its 10-year Governmentwide Acquisition Contract, effective Mar. 1.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 3:36 pm

LUNR

Intuitive Machines announced via Twitter that their Odysseus mission continues to operate on the lunar surface, indicating ongoing success in their lunar exploration efforts.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 3:30 pm